Niagen Bioscience (NAGE) Liabilities and Shareholders Equity (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $114.3 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $114.3 million, up 40.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $410.4 million (up 57.74% YoY), and the FY2025 annual result was $106.4 million, up 55.84% from the prior year.
• Liabilities and Shareholders Equity grew to $114.3 million in Q1 2026 per NAGE's latest filing, from $106.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $114.3 million in Q1 2026 and troughed at $45.7 million in Q3 2022.
• A 5-year average of $67.0 million and a median of $54.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity dropped 29.2% in 2022, then surged 73.63% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $54.1 million in 2022, then climbed by 1.68% to $55.0 million in 2023, then gained by 24.22% to $68.3 million in 2024, then soared by 55.84% to $106.4 million in 2025, then increased by 7.45% to $114.3 million in 2026.
• Business Quant data shows NAGE's Liabilities and Shareholders Equity at $114.3 million in Q1 2026, $106.4 million in Q4 2025, and $98.1 million in Q3 2025.